MedDRA preferred term · the product was stored wrongly

Incorrect product storage: adverse event reports recording this term

13,153 reports to FDA record it, 2006–2017; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

13,153
reports recording the term: 0.1% of all reports; 0
reports, 12 months to June 2026: 0 in the 12 months before; 14.3%
marked serious by the reporter: 57.4% across all reports; 0.4%
record death among outcomes, as reported: 9.1% across all reports

"Incorrect product storage" (in plain words, the product was stored wrongly) is a MedDRA preferred term recorded in 13,153 adverse event reports received by FDA, 0.1% of the database, from December 2006 to June 2017. The term is chosen by whoever codes the report to match what the reporter described.

0 reports recorded it in the 12 months to June 2026, and none in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 14.3% are marked serious, 0.4% include death among the outcomes and 5.7% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Enbrel, Humalog and Humira. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Enbrel	Tumor necrosis factor blocker	2,251	0.4%
Humalog	Insulin analog	969	1.4%
Humira	—	671	0.1%
Forteo	Parathyroid hormone analog	574	0.6%
Orencia	Selective T cell costimulation modulator	550	0.5%
Lantus Solostar	Insulin analog	437	1%
Simponi	Tumor necrosis factor blocker	393	0.6%
Stelara	Interleukin-12 antagonist	299	0.3%
Restasis	Calcineurin inhibitor immunosuppressant	226	1.2%
Epogen	Erythropoiesis-stimulating agent	181	4.2%
Opdivo	Programmed death Receptor-1 blocking antibody	176	0.4%
Sterile diluent	Insulin analog	174	5.4%
Humulin N	Insulin	167	1.5%
Nuvaring	Estrogen	161	0.9%
Humalog Mix75/25	Insulin analog	144	1.8%
Procrit	Erythropoiesis-stimulating agent	140	1.7%
Ventolin Hfa	beta2-Adrenergic agonist	133	0.6%
Xtandi	Androgen receptor inhibitor	121	0.3%
Risperdal Consta	—	109	0.8%
Prolia	RANK ligand inhibitor	106	0.1%
Humulin 70/30	Insulin	100	1.5%
Tanzeum	—	100	1.2%
Remicade	Tumor necrosis factor blocker	98	0.1%
Cosentyx	Interleukin-17A antagonist	96	0.1%
Solostar	—	90	0.8%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Tumor necrosis factor blocker	2,768	0.3%	0%
Insulin analog	2,043	0.7%	0.2%
Parathyroid hormone analog	596	0.6%	0.5%
Selective T cell costimulation modulator	584	0.4%	0.4%
Erythropoiesis-stimulating agent	388	0.6%	0%
Insulin	370	1%	0.4%
Corticosteroid	314	0%	0%
Interleukin-12 antagonist	299	0.3%	0.2%
Calcineurin inhibitor immunosuppressant	284	0.1%	0%
Estrogen	233	0.2%	0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.3%35

2 to 111.2%162

12 to 171%133

18 to 449.1%1,198

45 to 6419.4%2,551

65 to 749.4%1,237

75 and over5.8%764

Age not given53.8%7,073

Patient sex

Female52.5%6,904

Male29%3,817

Not given18.5%2,432

Grey bar: all 20,646,523 reports in the database. 95.7% of these reports give the United States as the country.

Questions about "Incorrect product storage"

What does "Incorrect product storage" mean in an adverse event report?

In plain language: the product was stored wrongly. It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record incorrect product storage?

13,153 reports through June 2026 (0.1% of all reports), 0 of them in the latest 12 months.

Which drugs appear most often in these reports?

Enbrel (2,251), Humalog (969), Humira (671), Forteo (574) and Orencia (550). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.